Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912925 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22643670 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL17815311 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21861811 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL19704788 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20935053 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22314405 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21998545 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL23877006 | 0.94 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20841072 | 0.93 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3626273-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3212668-B1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3458102-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| WO-2017201204-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017095805-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017095808-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885NPY5R 2662/4885NPY1R 4099/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885NPY5R 2662/4885NPY1R 4099/4885 |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | FAP 4279/4885NPY5R 4707/4885NPY1R 4604/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885NPY5R 3964/4885NPY1R 4608/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885NPY5R 3964/4885NPY1R 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.